CF
BLCM

Centaurus Financial’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Centaurus Financial’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-333
Closed -$25K – 2189
2018
Q2 		$25K Buy
+333
New +$26K ﹤0.01% 1192

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Centaurus Financial's BLCM Position: Q3 2018 in Review

Centaurus Financial sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2018, closing a stake of 333 shares — an estimated $25K sold.

Centaurus Financial first reported a position in BLCM in Q2 2018 and held it in 1 quarter. The position peaked at $25K in Q2 2018. 100 funds tracked by Wall St. Rank hold BLCM as of Q3 2018.

  • Centaurus Financial reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 333 Bellicum Pharmaceuticals, Inc. shares in Q3 2018, an estimated $25K.
  • Centaurus Financial first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Bellicum Pharmaceuticals, Inc. position peaked at $25K in Q2 2018.
  • 100 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.